Liquidia (LQDA) Return on Capital Employed (2021 - 2026)
Liquidia's (LQDA) quarterly Return on Capital Employed came in at 21.19% in Q1 2026, up 9717.0% year-on-year from 0.22% in Q1 2025, and up 168.54% quarter-over-quarter from 30.91% in Q4 2025.
Liquidia (LQDA) Return on Capital Employed (2021 - 2026) Analysis & Trends
Liquidia's Return on Capital Employed history runs 6 years deep, the most recent figure standing at 21.19% for Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 9717.0% year-over-year to 21.19% in Q1 2026; TTM through Mar 2026 was 21.19%, a 9717.0% increase from a year earlier, with the FY2025 full-year figure at 35.84%, up 5568.0% from the prior year.
- Return on Capital Employed grew to 21.19% in Q1 2026 per LQDA's latest filing, from 30.91% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 21.19% in Q1 2026 and bottomed at 84.28% in Q2 2025.
- The 5-year median for Return on Capital Employed is 51.16% (2023), against an average of 49.13%.
- Across the five-year window, Return on Capital Employed sank 4434 bps in 2023 and surged 9717 bps in 2026, its largest moves.
- Year by year, Return on Capital Employed stood at 31.76% in 2022, then slumped by 140 bps to 76.1% in 2023, then gained by 20 bps to 60.7% in 2024, then surged by 49 bps to 30.91% in 2025, then soared by 169 bps to 21.19% in 2026.
- Per Business Quant, the three latest LQDA Return on Capital Employed figures stand at 21.19% (Q1 2026), 30.91% (Q4 2025), and 65.51% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | Liquidia | 7.84 Bn | 7.61 Bn | 121.79 Mn | 21.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.19% |
| Dec 31, 2025 | -30.91% |
| Sep 30, 2025 | -65.51% |
| Jun 30, 2025 | -84.28% |
| Mar 31, 2025 | -75.98% |
| Dec 31, 2024 | -60.70% |
| Sep 30, 2024 | -61.57% |
| Jun 30, 2024 | -59.70% |
| Mar 31, 2024 | -68.45% |
| Dec 31, 2023 | -76.10% |
| Sep 30, 2023 | -51.16% |
| Jun 30, 2023 | -44.80% |
| Mar 31, 2023 | -27.43% |
| Dec 31, 2022 | -31.76% |
| Sep 30, 2022 | -33.99% |
| Jun 30, 2022 | -38.26% |
| Mar 31, 2022 | -45.85% |
| Dec 31, 2021 | -37.68% |
| Sep 30, 2021 | -40.25% |
| Jun 30, 2021 | -51.52% |